JP7365396B2 - Ｃｄｋ８／１９阻害薬 - Google Patents

Ｃｄｋ８／１９阻害薬 Download PDF

Info

Publication number
JP7365396B2
JP7365396B2 JP2021505964A JP2021505964A JP7365396B2 JP 7365396 B2 JP7365396 B2 JP 7365396B2 JP 2021505964 A JP2021505964 A JP 2021505964A JP 2021505964 A JP2021505964 A JP 2021505964A JP 7365396 B2 JP7365396 B2 JP 7365396B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
several
alkyl
several substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021505964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533143A5 (https=
JP2021533143A (ja
Inventor
ミンディッチ，アレクセイ・レオニドビッチ
チェストノバ，アンナ・ユレフナ
カサトキナ，マリーア・アンドレーフナ
アラフィノフ，アンドレイ・イワノビッチ
ガブリロフ，アレクセイ・セルゲエビッチ
エフドキモフ，アントン・アレクサンドロビッチ
レンシュミット，リリアナ・フヤチェスラホフナ
マクシメンコ，エレーナ・アレクサンドロフナ
ミシナ，マリーア・セルゲーブナ
シロノフ，セルゲイ・アレクサンドロビッチ
スミルノフ，エフゲニイ・ユーレビッチ
イアコフレフ，パベル・アンドレービッチ
モロゾフ，ドミトリ・バレンチノビッチ
Original Assignee
ジョイント・ストック・カンパニー “バイオキャド”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジョイント・ストック・カンパニー “バイオキャド” filed Critical ジョイント・ストック・カンパニー “バイオキャド”
Publication of JP2021533143A publication Critical patent/JP2021533143A/ja
Publication of JP2021533143A5 publication Critical patent/JP2021533143A5/ja
Application granted granted Critical
Publication of JP7365396B2 publication Critical patent/JP7365396B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021505964A 2018-08-03 2019-07-31 Ｃｄｋ８／１９阻害薬 Active JP7365396B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2018128415A RU2761824C2 (ru) 2018-08-03 2018-08-03 Ингибиторы CDK8/19
RU2018128415 2018-08-03
PCT/RU2019/050123 WO2020027704A1 (ru) 2018-08-03 2019-07-31 Ингибиторы cdk8/19

Publications (3)

Publication Number Publication Date
JP2021533143A JP2021533143A (ja) 2021-12-02
JP2021533143A5 JP2021533143A5 (https=) 2022-08-09
JP7365396B2 true JP7365396B2 (ja) 2023-10-19

Family

ID=69231230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021505964A Active JP7365396B2 (ja) 2018-08-03 2019-07-31 Ｃｄｋ８／１９阻害薬

Country Status (19)

Country Link
US (1) US11840531B2 (https=)
EP (1) EP3831829A4 (https=)
JP (1) JP7365396B2 (https=)
KR (1) KR102926889B1 (https=)
CN (1) CN113166140B (https=)
AR (1) AR115898A1 (https=)
AU (1) AU2019313199B2 (https=)
BR (1) BR112021001939A2 (https=)
CA (1) CA3108298A1 (https=)
CL (1) CL2021000282A1 (https=)
CO (1) CO2021001174A2 (https=)
EA (1) EA202190452A1 (https=)
MA (1) MA52375B2 (https=)
MX (1) MX2021001335A (https=)
PE (1) PE20210416A1 (https=)
PH (1) PH12021550258A1 (https=)
RU (1) RU2761824C2 (https=)
TW (1) TWI839374B (https=)
WO (1) WO2020027704A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533016A (ja) 2020-07-11 2023-08-01 ファイザー・インク 抗ウイルス性ヘテロアリールケトン誘導体
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2024109660A1 (zh) * 2022-11-21 2024-05-30 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532486A (ja) 2006-04-06 2009-09-10 ノバルティス アーゲー Ｐｄｋ１阻害のためのキナゾリン類
JP2011506336A (ja) 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
JP2017522324A (ja) 2014-07-17 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用
WO2017202719A1 (en) 2016-05-23 2017-11-30 Boehringer Ingelheim International Gmbh New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103249721B (zh) * 2010-10-18 2016-10-12 拉夸里亚创药株式会社 作为ttx-s阻滞剂的芳胺衍生物
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 １，７－萘啶衍生物
EP3383875B1 (en) * 2015-11-30 2022-02-09 Council Of Scientific & Industrial Research 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532486A (ja) 2006-04-06 2009-09-10 ノバルティス アーゲー Ｐｄｋ１阻害のためのキナゾリン類
JP2011506336A (ja) 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
JP2017522324A (ja) 2014-07-17 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用
WO2017202719A1 (en) 2016-05-23 2017-11-30 Boehringer Ingelheim International Gmbh New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors

Also Published As

Publication number Publication date
TW202012406A (zh) 2020-04-01
AU2019313199A1 (en) 2021-03-11
RU2018128415A (ru) 2020-02-04
PE20210416A1 (es) 2021-03-04
CO2021001174A2 (es) 2021-02-26
BR112021001939A2 (pt) 2021-04-27
MX2021001335A (es) 2021-04-12
CN113166140B (zh) 2024-06-14
CN113166140A (zh) 2021-07-23
EP3831829A1 (en) 2021-06-09
CL2021000282A1 (es) 2021-08-13
RU2761824C2 (ru) 2021-12-13
AR115898A1 (es) 2021-03-10
AU2019313199B2 (en) 2023-07-06
RU2018128415A3 (https=) 2021-03-30
EA202190452A1 (ru) 2021-04-13
US11840531B2 (en) 2023-12-12
MA52375B2 (fr) 2023-02-28
PH12021550258A1 (en) 2021-10-11
WO2020027704A1 (ru) 2020-02-06
TWI839374B (zh) 2024-04-21
MA52375A1 (fr) 2021-12-31
US20210246138A1 (en) 2021-08-12
KR102926889B1 (ko) 2026-02-19
EP3831829A4 (en) 2022-04-20
CA3108298A1 (en) 2020-02-06
KR20210040416A (ko) 2021-04-13
JP2021533143A (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
CN116457358A (zh) 作为ras抑制剂以治疗癌症的吲哚衍生物
JP7365332B2 (ja) Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
KR20180094939A (ko) 폴리시클릭 tlr7/8 안타고니스트 및 면역 질환의 치료에서 이들의 용도
JP7365396B2 (ja) Ｃｄｋ８／１９阻害薬
RU2763347C2 (ru) Новые ингибиторы cdk8/19
RU2754441C2 (ru) Новые ингибиторы cdk8/19
JP7284161B2 (ja) ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用
RU2851298C2 (ru) Новые ингибиторы JAK1-киназ
RU2852021C2 (ru) Новые ингибиторы JAK1-киназ
EA042225B1 (ru) Ингибиторы cdk8/19
RU2739489C2 (ru) Новые гетероциклические соединения как ингибиторы CDK8/19
HK40058347A (en) Cdk8/19 inhibitors
RU2786524C2 (ru) Ингибиторы рецептора эпидермального фактора роста
HK40058347B (zh) Cdk8/19抑制剂
KR20250078953A (ko) 사이클린-의존성 키나아제 7 억제제
CA3268634A1 (en) Cyclin-dependent kinase 7 inhibitors
TW202120511A (zh) 雜環化合物
BR112020002674B1 (pt) Compostos heterocíclicos como inibidoresde cdk8/19, método para inibir a atividade biológica de quinases de proteína, composição farmacêutica, método para tratamento de uma doença ou distúrbio e uso do composto ou sal farmaceuticamente aceitável do mesmo
EA041908B1 (ru) Производные 1,7-нафтиридина и их применение в качестве ингибиторов cdk8/19

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230803

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230911

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231006

R150 Certificate of patent or registration of utility model

Ref document number: 7365396

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150